Xiancai Ma

机构：Sun Yat-sen University, Guangzhou Experimental Station, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, State Key Laboratory of Respiratory Disease, Huazhong University of Science and Technology, South China University of Technology, Guangzhou Medical University · ORCID：0000-0002-4934-4221

发表论文 56 篇 · 总被引 2243 次 · h-index 22

代表论文

• Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia (2024 · Cell Reports Medicine · 被引 25)
• The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments (2024 · Molecular Cancer · 被引 23)
• The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis (2024 · Nature Immunology · 被引 18)
• The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2 (2024 · mBio · 被引 11)
• ORC1 enhances repressive epigenetic modifications on HIV-1 LTR to promote HIV-1 latency (2024 · Journal of Virology · 被引 7)
• Generation of a new therapeutic d-peptide that induces the differentiation of acute myeloid leukemia cells through A TLR-2 signaling pathway (2024 · Cell Death Discovery · 被引 7)